Literature DB >> 33746758

The Effects of Apelin and Elabela Ligands on Apelin Receptor Distinct Signaling Profiles.

Yunlu Jiang1, Maocai Yan2, Chunmei Wang1, Qinqin Wang1, Xiaoyu Chen3, Rumin Zhang1, Lei Wan1, Bingyuan Ji1, Bo Dong4, Huiyun Wang2, Jing Chen1,5.   

Abstract

Apelin and Elabela are endogenous peptide ligands for Apelin receptor (APJ), a widely expressed G protein-coupled receptor. They constitute a spatiotemporal dual ligand system to control APJ signal transduction and function. We investigated the effects of Apelin-13, pGlu1-apelin-13, Apelin-17, Apelin-36, Elabela-21 and Elabela-32 peptides on APJ signal transduction. Whether different ligands are biased to different APJ mediated signal transduction pathways was studied. We observed the different changes of G protein dependent and β-arrestin dependent signaling pathways after APJ was activated by six peptide ligands. We demonstrated that stimulation with APJ ligands resulted in dose-dependent increases in both G protein dependent [cyclic AMP (cAMP), Ca2+ mobilization, and the early phase extracellular related kinase (ERK) activation] and β-arrestin dependent [GRKs, β-arrestin 1, β-arrestin 2, and β2 subunit of the clathrin adaptor AP2] signaling pathways. However, the ligands exhibited distinct signaling profiles. Elabela-32 showed a >1000-fold bias to the β-statin-dependent signaling pathway. These data provide that Apelin-17 was biased toward β-arrestin dependent signaling. Eabela-21 and pGlu1-Apelin-13 exhibited very distinct activities on the G protein dependent pathway. The activity profiles of these ligands could be valuable for the development of drugs with high selectivity for specific APJ downstream signaling pathways.
Copyright © 2021 Jiang, Yan, Wang, Wang, Chen, Zhang, Wan, Ji, Dong, Wang and Chen.

Entities:  

Keywords:  Elabela; apelin; apelin receptor; arrestin; biased signaling

Year:  2021        PMID: 33746758      PMCID: PMC7970304          DOI: 10.3389/fphar.2021.630548

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  4 in total

1.  ERK/HIF-1α/VEGF pathway: a molecular target of ELABELA (ELA) peptide for attenuating cardiac ischemia-reperfusion injury in rats by promoting angiogenesis.

Authors:  Kamran Rakhshan; Masoomeh Sharifi; Fatemeh Ramezani; Yaser Azizi; Nahid Aboutaleb
Journal:  Mol Biol Rep       Date:  2022-09-21       Impact factor: 2.742

2.  Amidation-Modified Apelin-13 Regulates PPARγ and Perilipin to Inhibit Adipogenic Differentiation and Promote Lipolysis.

Authors:  Sha Wang; Guoying Gao; Yiwei He; Qiong Li; Zhan Li; Guoxiang Tong
Journal:  Bioinorg Chem Appl       Date:  2021-05-07       Impact factor: 7.778

3.  Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice.

Authors:  Andrea David Re Cecconi; Mara Barone; Mara Forti; Martina Lunardi; Alfredo Cagnotto; Mario Salmona; Davide Olivari; Lorena Zentilin; Andrea Resovi; Perla Persichitti; Dorina Belotti; Federica Palo; Nobuyuki Takakura; Hiroyasu Kidoya; Rosanna Piccirillo
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

Review 4.  Possible roles of exercise and apelin against pregnancy complications.

Authors:  Hamed Alizadeh Pahlavani
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.